Specific symptomatic changes following donepezil treatment of Alzheimer's disease: A multi-centre, primary care, open-label study

International Journal of Geriatric Psychiatry

Volumn 22, Issue 4, 2007, Pages 312-319

  Rockwood, Kenneth ^a   Black, Sandra ^b   Bedard, Marc Andre ^c   Tran, Thang ^d   Lussier, Isabelle ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^d PFIZER INC   (United States)

Author keywords

ADAS Cog; Alzheimer's disease; Behavior; Caregiver; Clinical meaningfulness; Clinical scales; Cognition; Donepezil; Treatment

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; APATHY; ARTICLE; ASTHENIA; ATTENTION; BEHAVIOR CHANGE; CAREGIVER; CAREGIVER BURDEN; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; LEG CRAMP; LEISURE; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHYSICIAN; PRIMARY MEDICAL CARE; RATING SCALE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SPATIAL ORIENTATION; SYMPTOM; SYMPTOM CHECKLIST 90; TIME PERCEPTION; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNPLEASANT DREAM; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATTENTION; CAREGIVERS; COST OF ILLNESS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; MALE; MENTAL RECALL; MENTAL STATUS SCHEDULE; MOTIVATION; NOOTROPIC AGENTS; ORIENTATION; PIPERIDINES; PRIMARY HEALTH CARE; STEREOTYPED BEHAVIOR; TREATMENT OUTCOME;

EID: 34247590897     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1675     Document Type: Article

References (23)

1. Berry JJ, Hurtado GI. 1994. Comparing non-independent proportions. Observations 3: 21-27.
2. Courtney C, Farrell D, Gray R, et al. 2004. Long term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double blind trial. Lancet 363: 2105-2115.
3. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
4. Davis KL, Marin DB, Kane R, et al. 1997. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 12: 978-988.
5. Feldman H, Schulzer M, Wang S, et al. 1995. The Functional Rating Scale in Alzheimer's disease assessment: a longitudinal study. In Research Advances in Alzheimer's Disease and Related Disorders, Iqbal K, Mortimer JA, Winblad B, Wisniewski HM (eds). John Wiley: London; 235-241.
6. Folstein M, Folstein S, McHugh P. 1975. 'Mini-Mental State': a practice method for grading the cognitive status of patients for the clinician. J Psychiatric Res 12: 189-198.
7. Gélinas I, Gauthier L, McIntyre M, Gauthier S. 1999. Development of a fundamental measure for persons with Alzheimer's disease: the disability Assessment for dementia. Am J Occupat Therapy 53: 471-481.
8. Kaduszkiewicz H. 2006. An innovative approach to involve patients in measuring treatment effects in drug trials. CMAJ 174: 1117-1118.
9. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. 2005. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 331: 321-327.
10. Kiresuk T, Sherman R. 1968. Goal attainment scaling: a general method for evaluating community mental health programs. Commun Mental Health J 4: 443-453.
11. McKhann G, Droachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944.
12. Olin JT, Schneider LS, Doody RS, et al. 1996. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol 9: 176-180.
13. Rockwood K, Joffres C. 2002. Halifax Consensus Conference on Understanding the Effects of Dementia Treatment. Improving clinical descriptions the effects of dementia treatment: consensus recommendations. Int J Geriatr Psych 17: 1006-1011.
14. Rockwood K, Graham JE, Fay S, et al. 2002. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 73: 500-507.
15. Rockwood K, Black SE, Robillard A, Lussier I. 2004. Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey. Int J Geriatr Psychiatry 19: 954-960.
16. Rockwood K, Fay S, Song X, et al. 2006. Attainment of goals in patients treated with galantamine: a randomized, controlled trial. CMAJ 174: 1099-1105.
17. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
18. Rothwell PM. 2005. External validity of randomised controlled trials: 'to whom do the results of this trial apply?'. Lancet 365: 82-93.
19. Royall DR, Lauterbach EC, Cummings JL, et al. 2002. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 14: 377-405.
20. Scott AJ. Seber GAF. 1983. Difference of proportions from the same survey. Am Statistician 37(4): 319-320.
21. Voss SE, Bullock RA. 2004. Executive function: the core feature of dementia? Dement Geriatr Cogn Disord 18: 207-216.
22. Wild CJ. Seber GAF. 1993. Comparing two proportions from the same survey. Am Statistician 37(4): 178-181.
23. Winblad H, Brodaty S, Gauthier S, et al. 2001. Pharmacotherapy of Alzheimer's Disease: is there a need to redefine treatment success? Int J Geriatr Psych 16: 653-666.